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Available TMA and FDG PET data
N=96
HNSCC cases treated with IMRT
N=142


























Supplementary Figure 1. Patient fl owchart. One hundred and two patients had tumor blocks cored for tissue microarray-making. 
 IHC, immunohistochemistry; TMA, tissue microarray; TSUVmax, maximal standardized uptake value in the tumor. 
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 Supplementary Table I. Patient characteristics, the 102 included patients. 
 No.of patients  Percent 
 No. of patients 102 100.0 %
 Age (years) 
Median 64.5
Range 33 – 84
 Sex 
Male 80 78.4 %
Female 22 21.6 %
 PS WHO 
0 68 66.7 %
1 – 3 34 33.4 %
 Primary site 
Nasopharynx 17 16.7 %
Oral cavity 7 6.9 %
Oropharynx 37 36.3 %
Hypopharynx 24 23.5 %
Larynx 17 16.7 %
 UICC stage 
I-III 18 17.6 %
IV 84 82.4 %
 T classifi cation 
T1 17 16.7 %
T2 37 36.3 %
T3 22 21.6 %
T4 26 25.5 %
 N classifi cation 
N0-N1 21 20.6 %
N2-N2b 39 38.2 %
N2c 29 28.4 %
N3 13 12.7 %
 Smoking history 
Never smoked 7 6.9 %
Former smoker 30 29.4 %
Current smoker 65 63.7 %
 Histological subtype 
Well differentiated SCC 3 2.9 %
Moderately differentiated SCC 39 38.2 %
Poorly differentiated SCC 22 21.6 %
Basaloid SCC 1 1.0 %
Non-keratinizing SCC of the oropharynx 23 22.5 %
Nasopharyngeal carcinoma 13 12.7 %
Transitional cell carcinoma 1 1.0 %
 PS who , World Health Organization performance status; UICC, Union for International Cancer 
Control. 
